<a class="ci-mono font-sans text-ink no-underline hover:text-accent" href="/gene/ABL1">ABL1 Fusion

Predictive

Supports Sensitivity Response

accepted

EID4436

Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with no secondary variants in at least ten bacterial clones generated using perip… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

BCR::ABL1 Fusion AND ABL1 E255K

Predictive

Supports Resistance

accepted

EID4718

Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with the E255K secondary variant in 3/12 bacterial clones generated using periphe… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

Acute Myeloid Leukemia2
BCR::ABL1 Fusion	Imatinib	Predictive	A	Supports Sensitivity Response	5	accepted	EID259 Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML. PMID 12476305 · Nimmanapalli et al., 2002 · Open in CIViC	civic
BCR::ABL1 Fusion	Imatinib	Predictive	D	Supports Resistance	3	accepted	EID232 BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines. PMID 12476305 · Nimmanapalli et al., 2002 · Open in CIViC	civic

Acute Myeloid Leukemia2

BCR::ABL1 Fusion

Predictive

Supports Sensitivity Response

accepted

EID259

Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML.

PMID 12476305 · Nimmanapalli et al., 2002 · Open in CIViC

BCR::ABL1 Fusion

Predictive

Supports Resistance

accepted

EID232

BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines.

PMID 12476305 · Nimmanapalli et al., 2002 · Open in CIViC

Acute Myeloid Leukemia with BCR-ABL13

Acute Myeloid Leukemia with BCR-ABL13
BCR::ABL1 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID12046 In this 2007 study, the authors identified 38 cases of t(9;22)(q34;q11), also known as Philadelphia positive (Ph+), acute leukemia of myeloid origin. However, 18 cases were excluded as they displayed … (full text at CIViC) PMID 17369142 · Soupir et al., 2007 · Open in CIViC	civic
BCR::ABL1 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID12047 In this 1996 study, the authors identified 11 cases of t(9;22)(q34;q11), also known as Philadelphia chromosome [BCR::ABL1], positive acute myeloid leukaemia (AML) from approximately 700 cases that had… (full text at CIViC) PMID 8952155 · Cuneo et al., 1996 · Open in CIViC	civic
BCR::ABL1 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID12048 In this 2010 study, the authors included 5876 acute myeloid leukaemia (AML) cases with successful karyotype analysis. The cytogenetic aberration t(9;22)(q34;q11) [known to result in a BCR::ABL1 fusion… (full text at CIViC) PMID 20385793 · Grimwade et al., 2010 · Open in CIViC	civic

BCR::ABL1 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID12046

In this 2007 study, the authors identified 38 cases of t(9;22)(q34;q11), also known as Philadelphia positive (Ph+), acute leukemia of myeloid origin. However, 18 cases were excluded as they displayed … (full text at CIViC)

PMID 17369142 · Soupir et al., 2007 · Open in CIViC

BCR::ABL1 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID12047

In this 1996 study, the authors identified 11 cases of t(9;22)(q34;q11), also known as Philadelphia chromosome [BCR::ABL1], positive acute myeloid leukaemia (AML) from approximately 700 cases that had… (full text at CIViC)

PMID 8952155 · Cuneo et al., 1996 · Open in CIViC

BCR::ABL1 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID12048

In this 2010 study, the authors included 5876 acute myeloid leukaemia (AML) cases with successful karyotype analysis. The cytogenetic aberration t(9;22)(q34;q11) [known to result in a BCR::ABL1 fusion… (full text at CIViC)

PMID 20385793 · Grimwade et al., 2010 · Open in CIViC

B Lymphoblastic Leukemia/Lymphoma4

B Lymphoblastic Leukemia/Lymphoma4
BCR::ABL1 Fusion	Bosutinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11287 In a phase I/II, open-label trial, 570 patients with Philadelphia chromosome–positive CML were enrolled. Patient cohorts included second-line chronic phase (CP) CML (n = 286), third-/fourth-line CP CM… (full text at CIViC) PMID 24345751 · Kantarjian et al., 2014 · Open in CIViC	civic
BCR::ABL1 Fusion	Dasatinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11235 In a phase 2, open-label trial, a cohort of 78 patients with BCR-ABL positive ALL received 60 mg/m2 of dasatinib daily for up to 24 months in combination with chemotherapy (AIEOP-BFM ALL 2000 multi-ag… (full text at CIViC) Open in CIViC	civic
BCR::ABL1 Fusion	Nilotinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11288 In this phase 1 dose-escalation study, 119 patients with imatinib-resistant, Ph-positive CML or acute lymphoblastic leukemia (ALL) to receive nilotinib orally at doses of 50 mg, 100 mg, 200 mg, 400 mg… (full text at CIViC) PMID 16775235 · Kantarjian et al., 2006 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 T315I	Ponatinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11236 In a phase 2, open-label trial, 449 patients with either CML or Philadelphia chromosome-positive ALL or has a BCR-ABL T315I mutation were enrolled and administered once daily 45 mg ponatinib. In the 3… (full text at CIViC) PMID 24180494 · Cortes et al., 2013 · Open in CIViC	civic

BCR::ABL1 Fusion

Predictive

Supports Sensitivity Response

submitted

EID11287

In a phase I/II, open-label trial, 570 patients with Philadelphia chromosome–positive CML were enrolled. Patient cohorts included second-line chronic phase (CP) CML (n = 286), third-/fourth-line CP CM… (full text at CIViC)

PMID 24345751 · Kantarjian et al., 2014 · Open in CIViC

BCR::ABL1 Fusion

Predictive

Supports Sensitivity Response

submitted

EID11235

In a phase 2, open-label trial, a cohort of 78 patients with BCR-ABL positive ALL received 60 mg/m2 of dasatinib daily for up to 24 months in combination with chemotherapy (AIEOP-BFM ALL 2000 multi-ag… (full text at CIViC)

Open in CIViC

BCR::ABL1 Fusion

Nilotinib

Predictive

Supports Sensitivity Response

submitted

EID11288

In this phase 1 dose-escalation study, 119 patients with imatinib-resistant, Ph-positive CML or acute lymphoblastic leukemia (ALL) to receive nilotinib orally at doses of 50 mg, 100 mg, 200 mg, 400 mg… (full text at CIViC)

PMID 16775235 · Kantarjian et al., 2006 · Open in CIViC

BCR::ABL1 Fusion AND ABL1 T315I

Ponatinib

Predictive

Supports Sensitivity Response

submitted

EID11236

In a phase 2, open-label trial, 449 patients with either CML or Philadelphia chromosome-positive ALL or has a BCR-ABL T315I mutation were enrolled and administered once daily 45 mg ponatinib. In the 3… (full text at CIViC)

PMID 24180494 · Cortes et al., 2013 · Open in CIViC

B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL14

B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL14
BCR::ABL1 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID12087 In this 1986 study the authors included 329 newly diagnosed patients with B-lymphoblastic leukemia (B-ALL), including 157 children and 172 adults. Cytogenetic analysis detected a t(9;22)(q34;q11) abno… (full text at CIViC) PMID 3455828 · Bloomfield et al., 1986 · Open in CIViC	civic
BCR::ABL1 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID12088 In this 1999 study the authors included 1322 B-lymphoblastic leukemia (B-ALL) cases in patients under the age of 21 years. Cytogenetic data showed that 30 cases (2.3%) had the t(9;22)(q34;q11) known t… (full text at CIViC) PMID 10194126 · Uckun et al., 1999 · Open in CIViC	civic
BCR::ABL1 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID12089 In this 1991 study the authors included 363 children diagnosed with B-lymphoblastic leukemia (B-ALL). Cytogenetic analysis idenitified a t(9;22) (q34;q11) also known as BCR::ABL1 in 15 cases (4.1%). T… (full text at CIViC) PMID 1991160 · Fletcher et al., 1991 · Open in CIViC	civic
BCR::ABL1 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID12090 In this large 2022 landscape study the authors include 2,754 children, adolescents and young adults (AYA) with newly diagnosed B-ALL (n=2,288 cases) or T-ALL (n=466). Median age at diagnosis was 6.4 y… (full text at CIViC) PMID 36050548 · Brady et al., 2022 · Open in CIViC	civic

BCR::ABL1 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID12087

In this 1986 study the authors included 329 newly diagnosed patients with B-lymphoblastic leukemia (B-ALL), including 157 children and 172 adults. Cytogenetic analysis detected a t(9;22)(q34;q11) abno… (full text at CIViC)

PMID 3455828 · Bloomfield et al., 1986 · Open in CIViC

BCR::ABL1 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID12088

In this 1999 study the authors included 1322 B-lymphoblastic leukemia (B-ALL) cases in patients under the age of 21 years. Cytogenetic data showed that 30 cases (2.3%) had the t(9;22)(q34;q11) known t… (full text at CIViC)

PMID 10194126 · Uckun et al., 1999 · Open in CIViC

BCR::ABL1 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID12089

In this 1991 study the authors included 363 children diagnosed with B-lymphoblastic leukemia (B-ALL). Cytogenetic analysis idenitified a t(9;22) (q34;q11) also known as BCR::ABL1 in 15 cases (4.1%). T… (full text at CIViC)

PMID 1991160 · Fletcher et al., 1991 · Open in CIViC

BCR::ABL1 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID12090

In this large 2022 landscape study the authors include 2,754 children, adolescents and young adults (AYA) with newly diagnosed B-ALL (n=2,288 cases) or T-ALL (n=466). Median age at diagnosis was 6.4 y… (full text at CIViC)

PMID 36050548 · Brady et al., 2022 · Open in CIViC

Chronic Myeloid Leukemia, BCR-ABL1 Positive22

Chronic Myeloid Leukemia, BCR-ABL1 Positive22
BCR::ABL1 Fusion	(diagnostic)	Diagnostic	A	Supports Positive	4	accepted	EID220 In this 2010 review, the authors highlighted the central diagnostic and pathogenic role of the BCR::ABL1 fusion gene in Chronic Myeloid Leukemia (CML), emphasizing that its presence is the characteriz… (full text at CIViC) PMID 20537386 · An et al., 2010 · Open in CIViC	civic
BCR::ABL1 Fusion	(prognostic)	Prognostic	B	Supports N/A	4	submitted	EID12434 Whole-genome sequencing of single-cell-derived hematopoietic clones from chronic myeloid leukemia (CML) patients revealed that the BCR::ABL1 fusion is acquired 3 to 14 years prior to clinical diagnosi… (full text at CIViC) PMID 40205062 · Kamizela et al., 2025 · Open in CIViC	civic
BCR::ABL1 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID12526 In this 2016 study, the authors analyzed 398 newly diagnosed Chronic Myeloid Leukemia (CML) patients, identifying 12 (3%) cases that lacked the Philadelphia (Ph) chromosome by conventional cytogenetic… (full text at CIViC) PMID 28404889 · Luatti et al., 2017 · Open in CIViC	civic
BCR::ABL1 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID12589 In this 2009 study, the authors included 336 chronic myeloid leukemia (CML) patients at diagnosis, of which 25 patients (7.44%) exhibited variant Philadelphia (Ph) chromosome translocations. A control… (full text at CIViC) PMID 19737651 · Bennour et al., 2009 · Open in CIViC	civic
BCR::ABL1 Fusion	(diagnostic)	Diagnostic	C	Does Not Support Positive	2	accepted	EID213 Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is no… (full text at CIViC) PMID 25212276 · Schmidt et al., 2014 · Open in CIViC	civic
BCR::ABL1 Fusion	Asciminib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11223 233 patients aged 18 or older who had Ph+ CML and were previously treated with two or more tyrosine kinase inhibitors were recruited to an open-label, multicentre phase 3 trial. The patients were rand… (full text at CIViC) PMID 34407542 · Réa et al., 2021 · Open in CIViC	civic
BCR::ABL1 Fusion	Asciminib	Predictive	A	Supports Sensitivity Response	4	submitted	EID12213 In the phase 3 ASC4FIRST trial (NCT04971226), patients with newly diagnosed Ph+ CML were randomized 1:1 to receive either asciminib (n=201) or an investigator-selected TKI (n=204). At week 48, major m… (full text at CIViC) PMID 38820078 · Hochhaus et al., 2024 · Open in CIViC	civic
BCR::ABL1 Fusion	Bosutinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11224 536 patients with CML, 487 of which were Philadelphia chromosome-positive were enlisted to a multicentre, open-label phase 3 trial assessing the efficacy and safety of bosutinib. The patients were ran… (full text at CIViC) PMID 29091516 · Cortes et al., 2018 · Open in CIViC	civic
BCR::ABL1 Fusion	Dasatinib	Predictive	C	Supports Sensitivity Response	4	accepted	EID4706 Prior to dasatanib treatment, fifteen imatinib-resistant patients with chronic myeloid leukemia in various phases had the BCR-ABL1 fusion with no secondary variants in at least ten clones generated us… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic
BCR::ABL1 Fusion	Imatinib	Predictive	A	Supports Sensitivity Response	5	accepted	EID260 The clinical use of imatinib in patients with BCR-ABL fusion has resulted in drastic prognostic improvements in patients with CML. PMID 20537386 · An et al., 2010 · Open in CIViC	civic
BCR::ABL1 Fusion	Imatinib	Predictive	A	Supports Sensitivity Response	5	accepted	EID344 BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens. PMID 20537386 · An et al., 2010 · Open in CIViC	civic
BCR::ABL1 Fusion	Dasatinib + NilotinibSubstitutes	Predictive	A	Supports Sensitivity Response	4	accepted	EID261 The use of nilotinib and dasatinib, second-generation BCR-ABL targeted therapies, has been effective in patients resistant to imatinib, leading to their FDA-approval. PMID 20537386 · An et al., 2010 · Open in CIViC	civic
BCR::ABL1 Fusion	Bafetinib + Dasatinib + NilotinibSubstitutes	Predictive	D	Supports Sensitivity Response	3	accepted	EID7838 In an in vitro study, six CML cell lines expressing the BCR-ABL1 fusion protein showed sensitivity to nilotinib (IC50: 24.3-84.5 nM), dasatinib (IC50: 1.5-10.9 nM), and bafetinib (IC50: 11.8-87.7 nM).… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 A365V	Dasatinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID4700 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 A366G	Dasatinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID4701 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 A397P	Dasatinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID4709 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 A397P	Dasatinib	Predictive	C	Does Not Support Resistance	1	accepted	EID4710 In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 A397P	Imatinib Mesylate	Predictive	C	Supports Resistance	1	accepted	EID7034 In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had A397P mutations. Both patients with A397P mutation achieved major hematologic response, and one also had major cytog… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 D276G	Axitinib	Predictive	D	Supports Resistance	2	accepted	EID4360 In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporations when harboring fusions with … (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 D276G	Bosutinib	Predictive	C	Does Not Support Resistance	1	accepted	EID4357 In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 D276G	Bosutinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID4356 In an in vitro study, a Ba/F3 murine cell line stably expressing the D276G mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with increased sensitivity to bosutinib treatment… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 D276G	Dasatinib	Predictive	C	Does Not Support Resistance	3	accepted	EID4359 This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic

BCR::ABL1 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID220

In this 2010 review, the authors highlighted the central diagnostic and pathogenic role of the BCR::ABL1 fusion gene in Chronic Myeloid Leukemia (CML), emphasizing that its presence is the characteriz… (full text at CIViC)

PMID 20537386 · An et al., 2010 · Open in CIViC

BCR::ABL1 Fusion

(prognostic)

Prognostic

Supports N/A

submitted

EID12434

Whole-genome sequencing of single-cell-derived hematopoietic clones from chronic myeloid leukemia (CML) patients revealed that the BCR::ABL1 fusion is acquired 3 to 14 years prior to clinical diagnosi… (full text at CIViC)

PMID 40205062 · Kamizela et al., 2025 · Open in CIViC

BCR::ABL1 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID12526

In this 2016 study, the authors analyzed 398 newly diagnosed Chronic Myeloid Leukemia (CML) patients, identifying 12 (3%) cases that lacked the Philadelphia (Ph) chromosome by conventional cytogenetic… (full text at CIViC)

PMID 28404889 · Luatti et al., 2017 · Open in CIViC

BCR::ABL1 Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID12589

In this 2009 study, the authors included 336 chronic myeloid leukemia (CML) patients at diagnosis, of which 25 patients (7.44%) exhibited variant Philadelphia (Ph) chromosome translocations. A control… (full text at CIViC)

PMID 19737651 · Bennour et al., 2009 · Open in CIViC

BCR::ABL1 Fusion

(diagnostic)

Diagnostic

Does Not Support Positive

accepted

EID213

Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is no… (full text at CIViC)

PMID 25212276 · Schmidt et al., 2014 · Open in CIViC

BCR::ABL1 Fusion

Asciminib

Predictive

Supports Sensitivity Response

submitted

EID11223

233 patients aged 18 or older who had Ph+ CML and were previously treated with two or more tyrosine kinase inhibitors were recruited to an open-label, multicentre phase 3 trial. The patients were rand… (full text at CIViC)

PMID 34407542 · Réa et al., 2021 · Open in CIViC

BCR::ABL1 Fusion

Asciminib

Predictive

Supports Sensitivity Response

submitted

EID12213

In the phase 3 ASC4FIRST trial (NCT04971226), patients with newly diagnosed Ph+ CML were randomized 1:1 to receive either asciminib (n=201) or an investigator-selected TKI (n=204). At week 48, major m… (full text at CIViC)

PMID 38820078 · Hochhaus et al., 2024 · Open in CIViC

BCR::ABL1 Fusion

Predictive

Supports Sensitivity Response

submitted

EID11224

536 patients with CML, 487 of which were Philadelphia chromosome-positive were enlisted to a multicentre, open-label phase 3 trial assessing the efficacy and safety of bosutinib. The patients were ran… (full text at CIViC)

PMID 29091516 · Cortes et al., 2018 · Open in CIViC

BCR::ABL1 Fusion

Predictive

Supports Sensitivity Response

accepted

EID4706

Prior to dasatanib treatment, fifteen imatinib-resistant patients with chronic myeloid leukemia in various phases had the BCR-ABL1 fusion with no secondary variants in at least ten clones generated us… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

BCR::ABL1 Fusion

Predictive

Supports Sensitivity Response

accepted

EID260

The clinical use of imatinib in patients with BCR-ABL fusion has resulted in drastic prognostic improvements in patients with CML.

PMID 20537386 · An et al., 2010 · Open in CIViC

BCR::ABL1 Fusion

Predictive

Supports Sensitivity Response

accepted

EID344

BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens.

PMID 20537386 · An et al., 2010 · Open in CIViC

BCR::ABL1 Fusion

Dasatinib + NilotinibSubstitutes

Predictive

Supports Sensitivity Response

accepted

EID261

The use of nilotinib and dasatinib, second-generation BCR-ABL targeted therapies, has been effective in patients resistant to imatinib, leading to their FDA-approval.

PMID 20537386 · An et al., 2010 · Open in CIViC

BCR::ABL1 Fusion

Bafetinib + Dasatinib + NilotinibSubstitutes

Predictive

Supports Sensitivity Response

accepted

EID7838

In an in vitro study, six CML cell lines expressing the BCR-ABL1 fusion protein showed sensitivity to nilotinib (IC50: 24.3-84.5 nM), dasatinib (IC50: 1.5-10.9 nM), and bafetinib (IC50: 11.8-87.7 nM).… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

BCR::ABL1 Fusion AND ABL1 A365V

Predictive

Supports Sensitivity Response

submitted

EID4700

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

BCR::ABL1 Fusion AND ABL1 A366G

Predictive

Supports Sensitivity Response

submitted

EID4701

PMID 19779040 · Müller et al., 2009 · Open in CIViC

BCR::ABL1 Fusion AND ABL1 A397P

Predictive

Supports Sensitivity Response

submitted

EID4709

PMID 19779040 · Müller et al., 2009 · Open in CIViC

BCR::ABL1 Fusion AND ABL1 A397P

Predictive

Does Not Support Resistance

accepted

EID4710

In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC)

PMID 17264298 · Guilhot et al., 2007 · Open in CIViC

BCR::ABL1 Fusion AND ABL1 A397P

Imatinib Mesylate

Predictive

Supports Resistance

accepted

EID7034

In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had A397P mutations. Both patients with A397P mutation achieved major hematologic response, and one also had major cytog… (full text at CIViC)

PMID 17264298 · Guilhot et al., 2007 · Open in CIViC

BCR::ABL1 Fusion AND ABL1 D276G

Axitinib

Predictive

Supports Resistance

accepted

EID4360

In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporations when harboring fusions with … (full text at CIViC)

PMID 25686603 · Pemovska et al., 2015 · Open in CIViC

BCR::ABL1 Fusion AND ABL1 D276G

Predictive

Does Not Support Resistance

accepted

EID4357

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

BCR::ABL1 Fusion AND ABL1 D276G

Predictive

Supports Sensitivity Response

submitted

EID4356

In an in vitro study, a Ba/F3 murine cell line stably expressing the D276G mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with increased sensitivity to bosutinib treatment… (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

BCR::ABL1 Fusion AND ABL1 D276G

Predictive

Does Not Support Resistance

accepted

EID4359

This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC